Adage Capital Partners GP L.L.C. Purchases New Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Adage Capital Partners GP L.L.C. bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 303,000 shares of the biopharmaceutical company's stock, valued at approximately $9,957,000. Adage Capital Partners GP L.L.C. owned 0.53% of Agios Pharmaceuticals as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC bought a new position in Agios Pharmaceuticals in the 4th quarter worth approximately $33,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth $53,000. Sterling Capital Management LLC increased its position in Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after acquiring an additional 1,587 shares during the period. KBC Group NV raised its stake in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 611 shares during the last quarter. Finally, AlphaQuest LLC raised its stake in Agios Pharmaceuticals by 106.2% during the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after purchasing an additional 2,338 shares during the last quarter.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.93% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Finally, Scotiabank reduced their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $56.00.

Agios Pharmaceuticals Trading Down 2.7 %

NASDAQ:AGIO traded down $0.84 during mid-day trading on Friday, hitting $30.10. The company's stock had a trading volume of 415,741 shares, compared to its average volume of 700,873. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of 2.65 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The stock has a fifty day moving average of $29.81 and a 200-day moving average of $37.80.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.